UEEC · United Health Products, Inc.

Summary

United Health Products sustained zero revenue in FY2025 while operating and net losses widened due to elevated stock-based compensation from RSU vesting, despite professional expense reductions from consultant terminations, as resources stayed focused on Class III PMA pursuit.

Key takeaways

• No revenue of $0 in FY2025, consistent with FY2024, reflecting full allocation of capital toward Class III PMA for CelluSTAT hemostatic technology.
• Operating loss increased 12.3% to -$2.3M from -$2.0M, driven by higher stock-based compensation offset by professional expense cuts.
• Net loss expanded 33.4% to -$2.7M from -$2.0M due to increased operating expenses and other expenses.
• Diluted EPS stable at -$0.01 year-over-year amid ongoing losses.
• Net cash used in operating activities remained comparable at -$1.2M, signaling steady cash burn during PMA development.